David L. Coleman

Wade Professor and ChairmanColeman_David-54-2-5x3-5-crp

Education:

9/1995 M.A. Yale University (Hon)

6/1976 M.D. University of California, San Francisco

6/1972 A.B. Stanford University

General field of research:

Infectious Disease

Affiliations other than medicine:

2009 – present Member, APM Clinical Care Committee

2003 – present Fellow, American College of Physicians

2003 – present Association of Professors of Medicine

1997 – present Editorial Board, Infection

1985 – present Infectious Disease Society of America

10/2006 – present Boston Medical Center, Boston, MA:
Board of Trustees
Medical Executive Committee
Finance Committee
Nominating and Governance Committee
Board of Trustees, Faculty Practice Plan
Marketing Committee
Clinical Quality Council
Clinical Technology Assessment Council

10/2006 – present Boston University School of Medicine, Boston, MA:
Chair, Clinical Chiefs’ Committee
Executive Committee
Patent Committee
BUSM in Abu Dhabi Planning Committee
Conflict of Interest Committee
BU Ad hoc Committee on Individual Conflict of Interest
BU Ad hoc Committee on Institutional Conflict of Interest

Contact information:

Office
Evans 113
Phone: (617)-638 7254
Fax: (617)-638 8728

colemand@bu.edu

Keywords:

Chairman; Department of Medicine

Summary of scholarly interest

The initial focus of Dr. Coleman’s original scholarship was in the regulation of macrophage activation and proliferation. He identified novel factors that induce macrophage phagocytic function and oxidative metabolism. He went on to characterize the mechanisms by which macrophages are activated, recruited, retained, and induced to proliferate in local tissues. His research team discovered production of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) by non-immunological cell and tissue types such as keratinocytes (skin), glomerular mesangial cells (kidney), and respiratory epithelium (trachea). His team also identified production of other soluble cytokines (Macrophage CSF and Interleukin 6) by local tissues that regulate cell traffic and inflammation, particularly in the skin and kidney – two common sites of inflammation and infection. His later studies focused on the subcellular mechanisms of macrophage activation and proliferation induced by GM-CSF. His further delineated the effect of GM-CSF on intracellular second messenger pathways (e.g., cyclic nucleotides, protein kinase C) and early response genes (e.g., Egr-1) in macrophages. He defined the role of cis-acting 3’ regulatory elements in mediating the transcriptional activation of Egr-1 in macrophages. These studies were designed to characterize paracrine and autocrine signals that regulate cells in local tissues in states of inflammation and infection, and to better understand how therapies might be targeted at the extracellular and intracellular signals that underlie the inflammatory process. His work over the past 15 years has focused on medical and civic professionalism in medical education and clinical practice. He has developed incentive plans that promote physician productivity in an academically affiliated VA Medical Center and at Yale School of Medicine. In addition, he has led efforts at Yale and Boston University Schools of Medicine to develop more effective and rigorous policies for the interactions of clinicians with the pharmaceutical and medical device industries. Dr. Coleman’s clinical responsibilities include serving as an inpatient medical attending and infectious disease consult attending at Boston Medical Center.

Recent publications:

Coleman, DL.  2008.  Establishing policies for the relationship between industry and clinicians: lessons learned from two academic health centers. Academic Medicine 83(9):882-7.

Coleman, DL. 2006.  Impact of the Lack of Health Insurance: How Should Academic Medical Centers and Medical Schools Respond? Academic Medicine 81:728-731.

Wilson, MS, Joiner, KA, Inzucchi, SE, Mulligan G, Mechem, M, Gross, CP, Coleman, DL.  2006.  Improving clinical productivity in the academic setting: A novel incentive plan based on Utility Theory. Academic Medicine 81:306-316.

Coleman, DL, Kazdin, AE, Miller LA, Morrow, JS, Udelsman, R. 2006.  Guidelines for the Interactions between clinical faculty and the pharmaceutical industry: One medical school’s approach. Academic Medicine 81:154-159.

Coleman DL, Moran E, Serfilippi D, Mulinski P, Rosenthal R, Gordon B, Mogielnicki RP.  2003.   Measuring physician productivity in a Veterans Affairs Medical Center. Academic Medicine 78:682-689.

Shapiro ED, Coleman DL.  2000.  Scholarship of Application. Academic Medicine 75:895-898.

Chaturvedi S, Qi H, Coleman D, Rodriguez D, Hanson PI, Striepen B, Roos DS, Joiner KA.  1999.  Constitutive calcium independent release of Toxoplasma gondii dense granules occurs through the NSF/SNAP/SNARE/Rab machinery. J.Biol.Chem 274:2424-2431.

Budde K, Neumayer HH, Salant DJ, Cybulsky AV, Coleman DL, Sterzel RB.  1997.  Glomerular epithelial cell products stimulate mesangial cell proliferation in culture. Kidney International 52:733-41.